ProText Mobility Issues Strategic Update on Tokenization and Uplisting

ProText Mobility ( (TXTM) ) has provided an update.

On March 13, 2026, ProText Mobility issued a comprehensive strategic update outlining discretionary stock purchases by its president and chairman, who has only been accumulating TXTM shares, as well as its continued avoidance of executive salaries, debt, and reverse stock splits to support shareholder value. The company detailed liquidity arrangements with BNY Mellon, Standard Bank, Absa, and Melville Douglas via custodial wallets, alongside a custodial wallet pilot program aimed at supporting foreign direct trade and the influx of foreign equities.

ProText highlighted its use of a blockchain-enabled RWA tokenization platform, combined with proprietary kettle tech and nano-technology, to improve bioavailability of active pharmaceutical ingredients and unlock new tokenized asset revenue streams. It also emphasized its HULE reinvestment strategy, the expected balance-sheet uplift from seed stock and the TruLeaf LOI under IFRS standards, and progress toward IFRS-audited financials and a Deloitte valuation as stepping stones to a planned uplisting to a major exchange.

Additional initiatives disclosed included development of a new corporate website with an integrated investor relations suite, voluntary use of the SEC’s EDGAR system to enhance disclosure transparency, and positioning to benefit from favorable USD/ZAR foreign exchange movements. ProText further underscored its ESG and sustainability focus, including integrating carbon credits into its tokenization system and pursuing a zero-waste, environmentally aligned business model to support long-term growth and shareholder value.

More about ProText Mobility

ProText Mobility Inc. is a biotech company focused on research, testing, and development of highly bioavailable botanical formulations for nutraceutical and pharmaceutical applications. Leveraging proprietary live-plant extraction, nano-technology, and “kettle tech,” it also positions itself as a leader in blockchain-enabled real-world asset tokenization and compliant RWA solutions targeting global health and wellness markets.

The company integrates its biotech assets with tokenization platforms to create digital representations of active pharmaceutical ingredients and other real-world assets, aiming to enhance liquidity and capital flexibility. Its strategy emphasizes zero debt, financial discipline without executive salaries, and protection against shareholder dilution, while pursuing an uplisting to a major securities exchange and broader institutional investor access.

Current Market Cap: $58.51M

See more data about TXTM stock on TipRanks’ Stock Analysis page.